Decreased serum lipids in patients with probable Alzheimer's disease

Bosnian Journal of Basic Medical Sciences

Volumn 9, Issue 3, 2009, Pages 215-220

  Lepara, Orhan ^a   Valjevac, Amina ^a   Alajbegović, Azra ^a   Zaćiragic, Asija ^a   Nakaś Ićindic, Emina ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Alzheimer's disease; Cognitive impairment; Lipids; Mini mental state examination

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPIDS; MALE; TRIGLYCERIDES;

EID: 70349903270     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2009.2809     Document Type: Article

References (31)

1. Zaciragic A., Lepara O., Valjevac A., et al. Elevated serum C-reactive protein concentration in Bosnian patients with probable Alzheimer's disease. J. Alzheimers. Dis. 2007; 12:151-156.
2. Dimopoulos N., Piperi C., Salonicioti A., et al. Characterization of the lipid profile in dementia and depression in the elderly. J. Geriatr. Psychiatry Neurol. 2007; 20:138-144
3. Mielke M.M., Zandi P.P., Sjögren M., et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005:64:1689-1695.
4. Kivipelto M., Helkala E.L., Laakso M.P., et al. Apolipoprotein E epsiloiH allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 2002; 137:149-155.
5. Launer L.J., White L.R., Petrovitch H., Ross G.W., Curb J.D. Cho- (21) lesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001; 57:1447-11152
6. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003:61:199-205.
7. van Exel E., de Craen A.J., Gussekloo J., et al. Association between high-density lipoprotein and cognitive impairment in the oldestold. Ann. Neurol. 2002; 51:716-721.
8. Wolf H., Hensel A., Arendt T., Kivipelto M., Winblad B., Gertz H.J. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol. 2004;56(5):745-748
9. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a crosssectional analysis from the PAQUID study. Neuroepidemiology. 2000; 19:141-148.
10. Merched A., Xia Y., Visvikis S., Serot J.M., Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging. 2000; 21:27-30.
11. Moroney J.T., Tang M.X., Berglund L., Small S., Merchant C., et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282(3):254-260.
12. Romas S.N., Tang M.X., Berglund L., Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 1999; 53:517-521.
13. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 2004; 61:705-714.
14. Kuusisto J., Koivisto K., Mykkänen L., Helkala E.L., Vanhanen M., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ1997; 315:1045-1049.
15. Li G., Shofer J.B., Kukull W.A., Peskind E.R., Tsuang D.W., et al. Serum cholesterol and risk of Alzheimer disease: a community based cohort study. Neurology. 2005; 65:1045-1050.
16. Tan Z.S., Seshadri S., Beiser A., Wilson P.W., Kiel D.P., et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch. Intern. Med. 2003; 163:1053-1057.
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-944.
18. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
19. Launer L.J. Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology. 1992:11 Suppl 1:2-13.
20. Fillenbaum G.G, George L.K., Blazer D.G. Scoring nonre-sponse on the Mini-Mental State Examination. Psychol Med. 1988;l8(4):1021-1025.
21. Moroney J.T., Bagiella E., Desmond D.W., Hachinski V.C., Mölsä P.K., et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997; 49:1096-1105.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18:499-502.
23. Masse I., Bordet R., Deplanque D., Al Khedr A., Richard F., et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005; 76:1624-1629.
24. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998; 17:14-20.
25. Kivipelto M., Helkala E.L., Laakso M.P., Hänninen T., Hallikainen M., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447-1451.
26. Sparks D.L., Scheff S.W., Hunsaker J.C. 3rd, Liu H., Landers T., Gross D.R. Induction of Alzheimer-like beta-amyloid immuno-reactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994; 126:88-94.
27. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U S A. 1998 26:95:6460-6464.
28. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001; 98:5856-5861.
29. Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992; 86:1046-1060.
30. Dziedzic T., Slowik A., Gryz E.A., Szczudlik A. Lower serum trig-lyceride level is associated with increased stroke severity. Stroke. 2004;35:e151-152.
31. Henderson V.W., Guthrie J.R., Dennerstein L. Serum lipids and memory in a population based cohort of middle age women. J. Neurol. Neurosurg. Psychiatry. 2003; 74:1530-1535.